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The mainstay of malaria diagnosis relies on rapid diagnostic tests (RDTs) and microscopy, both of which lack analytical sensitivity. 
This leads to repeat testing to rule out malaria. A prospective diagnostic trial of the Meridian illumigene Malaria assay (loop-me-
diated isothermal amplification [LAMP]) was conducted comparing it with reference microscopy and RDTs (BinaxNOW Malaria) 
in returning travelers between June 2017 and January 2018. Returning travelers with signs and symptoms of malaria were enrolled 
in the study. RDTs, microscopy, and LAMP assays were performed simultaneously. A total of 298 patients (50.7% male; mean age, 
32.5 years) were enrolled, most visiting friends and relatives (43.3%), presenting with fever (88.9%), not taking prophylaxis (82.9%), 
and treated as outpatients (84.1%). In the prospective arm (n = 348), LAMP had a sensitivity of 98.1% (95% confidence interval 
[CI], 90.0%–100%) and a specificity of 97.6% (95% CI, 95.2%–99.1%) vs microscopy. After discrepant resolution with real-time 
polymerase chain reaction, LAMP had a sensitivity of 100% (95% CI, 93.7%–100%) and a specificity of 100% (95% CI, 98.7%–100%) 
vs microscopy. After discrepant resolution, RDTs had a sensitivity of 83.3% (95% CI, 58.6%–96.4%) and a specificity of 96.2% (95% 
CI, 93.2%–98.1%) vs microscopy. When including retrospective specimens (n = 377), LAMP had a sensitivity of 98.8% (95% CI, 
93.2%–100%) and a specificity of 97.6% (95% CI, 95.2%–99.1%) vs microscopy, and after discrepant resolution of this set, LAMP had 
a sensitivity of 100% (95% CI, 95.8%–100%) and a specificity of 100% (95% CI, 98.7%–100%). A cost-benefit analysis of reagents and 
labor suggests savings of up to USD$13 per specimen using a novel algorithm with LAMP screening.
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In 2016, there were approximately 216 million cases of malaria 
in 91 countries, resulting in 445  000 deaths [1]. The World 
Health Organization (WHO) African Region bears the larg-
est burden, with around 90% of the malaria cases. The WHO 
guidelines recommend that all suspected cases of malaria be 
confirmed with microscopy and/or rapid diagnostic tests. In 
Canada, there are on average 488 malaria cases per year across 
the country [2], and approximately 1700 annually in the United 
States [3]. However, in nonendemic settings such as North 
America, the vast majority of tests performed are negative.
Globally, the diagnosis of malaria is achieved with microscopy 
and rapid diagnostic tests (RDTs), or a combination of these. The 
WHO estimates that around 204 million patients were tested 
by microscopy and 269 million rapid diagnostic tests were sold 
in 2016 [4]. Although the increasing use of diagnostic-based 
treatment rather than symptom-based treatment undoubtedly 
has significant benefits, it is not without limitations. Microscopy 
has been found to have a limit of detection (LOD) of 50–100 
parasites/μL under field conditions [5, 6]. However, this can 
only be achieved when laboratory facilities are available, along 
with a specialized microscopist. Studies have found that the 
LOD varies depending on the training and experience of the 
microscopist [7]. The method is labor-intensive and requires 
constant quality assurance. Due to these limitations, and 
therefore the possibility of false negatives, the Centers for 
Disease Control and Prevention (CDC) in the United States and 
Public Health Canada both recommend that 3 malaria slides 
be taken [8, 9]. This is not just an inconvenience to the patient, 
who may have to return the emergency room several times; it 
results in increased health care costs due to re-attendance and 
increased laboratory time.
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Although RDTs have demonstrated a sensitivity and specific-
ity >90% for Plasmodium falciparum infections with >200 par-
asites/μL, they cannot reliably diagnose cases with parasitemia 
below this level [10]. Additionally, false-negative RDT results 
can occur from parasites that do not produce histidine-rich pro-
tein 2 (HRP2), a growing concern in malaria-endemic regions 
[11–13]. Molecular testing such as polymerase chain reaction 
(PCR) can achieve an LOD of 1 parasites/μL with improved 
sensitivity, but these tests are expensive and simply not feasible 
without a well-equipped laboratory and expertise [14].
Given the limitations with the current testing methods of 
microscopy, RDTs, and PCR, there has been interest in validat-
ing simpler nucleic acid tests (NATs) such as loop-mediated iso-
thermal amplification (LAMP) [15–19]. LAMP is a technology 
that was developed in 2000 that uses unique DNA polymerases 
and specially designed primers to amplify nucleic acid without 
thermocyclers [20]. LAMP can differentiate species, and varia-
tions can even be used to detect the C580Y mutation in the pro-
peller domain of the kelch 13 gene, the most prevalent marker of 
artemisinin resistance [21]. The LOD varies slightly depending 
on the exact protocol used, but it can achieve limits of detec-
tion of ≤2 parasites/μL, similar to those achieved by PCR and 
surpassing those of microscopy and RDTs [22–25]. The illumi-
gene Malaria LAMP assay (illumigene M; Meridian Biosciences, 
Cincinatti, OH) has shown good sensitivity and specificity vs 
microscopy, the current gold standard [15]. It performs well in 
terms of technological simplicity and cost. Commercial LAMP 
technology has been assessed against PCR in a number of stud-
ies, with extremely encouraging results (Table  1) [15–18, 22, 
25–28]. Given the excellent negative predictive value properties 
of LAMP in malaria, our group has proposed replacing the cur-
rent testing algorithm, which relies on 3 microscopy tests to rule 
out infection, with a single LAMP test [15]. This would improve 
testing turnaround time, optimize use of the emergency room, 
and reduce cost to the health care system.
On a global note, if elimination is to be achieved, a diagnostic 
tool with a lower limit of detection is required. A recent study 
modeling eradication showed that reducing the limit of detec-
tion of a diagnostic test increased the detection of the asymp-
tomatic infectious reservoir [29]. LAMP meets this criterion, 
and several studies have described the role it could play in 
malaria elimination [10, 25, 26, 30, 31].
Although LAMP has been shown in studies to surpass micros-
copy and RDTs, many studies to date have been retrospective 
in nature. In addition, studies have often focused on P.  falcip-
arum rather than all species of malaria. Our study was designed 
to closely reflect testing scenarios in North America. A  sin-
gle-center evaluation of LAMP performance against microscopy 
for all species of malaria in a major urban center (1.4 million 
people) was conducted. The primary objective of the study was 
to compare the clinical performance of a commercially available 
LAMP method (illumigene M) vs RDT (BinaxNOW) compared 
with microscopy in symptomatic patients presenting as potential 
cases of malaria in a nonendemic area. The secondary objective 
was to determine if certain clinical and epidemiological factors 
predicted malaria test results using regression analysis.
METHODS
Study Design, Patient Enrollment, and Ethics
The study design was pragmatic, containing both prospective 
and retrospective arms to provide an adequate distribution of 
all species of malaria. In the prospective arm, adult participants 
who underwent malaria testing were consecutively enrolled into 
the study from June 2017 until January 2018. Based on sample 
size calculation, a goal of 350 specimens was set with at least 
10% overall positivity for all species of malaria. To achieve this, 
Table 1. Commercial LAMP Performance Against PCR
Article Commercial Kit Specimen Analysisb Location
Sensitivity
(95% CI), %
Specificity
(95% CI), %
Aydin-Schmidt 2014 Eiken Retrospective Zanzibar – pre-elimination 91.5 (84.8–95.8) 100 (99.5–100)
Hopkins 2013 Eiken Prospective Uganda – high endemicity 90.0 (85.0–94.0) 85.0 (75.0–92.0)
Lucchi 2016 illumigene Prospective and retrospective Senegal – low endemicity 97.2 (92.6–99.1) 93.8 (84.2–98.0)
Marti 2015 Eiken Prospective Switzerland – returning travelers 100 (92.4–100) 100 (97.7–100)
Polley 2013 Eiken Prospective UK – returning travelers 97.0 (89.6–99.6) 99.2 (98.1–99.7)
Ponce 2017 illumigene Prospective France – returning travelers 100 (95.8–100) 98.1 (95.3–99.5)
Rypien 2017 illumigene Retrospective Canada – returning travelers 97.3 (90.7–99.7) 93.8 (84.8–98.3)
Sema 2015a Eiken Retrospective Ethiopia - moderate endemicity 96.8 (83.2–99.5) 84.3 (71.4–92.9)
Tegegne 2017 Eiken Retrospective Ethiopia - moderate endemicity 100 (100–100) 93.5 (86.5–100)
Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction.
aField values taken.
b"Prospective" defined as blood specimens tested within 72 hours without preservation; others considered "retrospective".
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testing was performed on a continuous basis with interrup-
tions only to ensure that enough positive samples were tested. 
Samples arriving at night were tested first thing in the morning 
by medical laboratory technologists using the LAMP technol-
ogy. All prospectively enrolled participants had epidemiological 
data collected through a case history form that accompanied the 
specimens. Variables recorded included whether pretravel advice 
was received, reason for travel, country visited, symptoms, sever-
ity, whether the participant took antimalarial prophylaxis, and 
whether they were on treatment. In addition to the prospective 
arm of the study, 29 microscopy confirmed malaria specimens 
were retrospectively collected and included in the study. This 
design has been used by other studies, and it allows an adequate 
sample size for rare non–P.  falciparum species [32]. Without 
this, due to the otherwise prospective nature of the study, only 
a small number of positive specimens for these species would 
have been included. Five Plasmodium vivax and 5 Plasmodium 
ovale frozen whole-blood specimens (at –80°C) were obtained 
from a large teaching hospital in Edmonton, Canada. Thirteen 
Plasmodium malariae specimens were frozen whole-blood 
specimens obtained from Pará, Brazil, and 6 culture-derived 
Plasmodium knowlesi (A1-H.1 clone) specimens of varying 
parasitemia (range, 0.1–10 000 parasite per μL) were obtained 
from London, United Kingdom. Retrospective specimens were 
thawed and underwent the same LAMP testing protocol as the 
prospective arm. No epidemiological data were available on ret-
rospective specimens. Ethical approval was obtained from the 
Conjoint Health Research Ethics Board (REB17-2220), and pri-
vacy review from Alberta Health Services.
Routine Laboratory Testing for Malaria
Venous whole-blood samples were collected in EDTA vacutain-
ers from medical centers in Calgary and the surrounding area 
and transported to Calgary Laboratory Services (CLS). CLS is a 
large centralized public microbiology laboratory service cover-
ing 1.4 million people. Samples from malaria-positive patients 
who were initially symptomatic, treated, and then retested 
were included in the study. Each specimen was tested accord-
ing to standard operating procedure: Giemsa-stained thick and 
thin peripheral blood smears and RDTs (BinaxNOW Malaria, 
Alere, Waltham, MA) on study participants. For the purposes 
of analysis, microscopy repeated 3 times from the same individ-
ual to confirm negativity was classified once only. Microscopy, 
RDTs, and LAMP testing were conducted in real time by the 
same technologist who was trained in all diagnostic tests due to 
personnel availability.
Malaria Testing With illumigene M LAMP
illumigene Malaria (Meridian Biosciences, Cincinatti, OH) is 
a commercially available, loop-mediated amplification test 
that detects all species of human malaria. The assay provides a 
positive or negative result only and does not speciate. Medical 
laboratory technologists received training for the LAMP assay. 
Testing using LAMP occurred simultaneously with current 
standard operating procedure (SOP) for the duration of the 
study. Specimens received at night were tested by LAMP in 
the day shift due to technologist availability. LAMP was per-
formed according to the manufacturer’s recommendations. 
Complete standard operating procedures for illumigene are 
available online (http://www.meridianbioscience.eu/media/
pdf/Package%20Insert/280925_281125_MULTI_REV1215.
pdf). Samples were frozen once at –80°C for subsequent real-
time PCR (RT-PCR) analysis, which was performed off-site in 
a blinded manner.
Discrepancy Resolution
Discrepant results occurred when the results of microscopy and 
the LAMP assay results were different. All microscopy-pos-
itive and discrepant specimens underwent RT-PCR testing at 
an off-site location at the Provincial Reference Laboratory in 
Edmonton, Canada, in a blinded manner. The RT-PCR method 
was clinically validated and used routinely at the reference labo-
ratory [33]. Concordant negative specimens were also tested by 
RT-PCR in Calgary, Canada.
Statistical Analysis
Data were tabulated in Microsoft Excel, version 16.11.1, and 
were analyzed using Stata, version 13.0. Crude statistical ana-
lysis of epidemiological dichotomous variables was determined 
using chi-square or Fisher exact statistical tests; t tests were used 
for comparison of means. Variables found to be statistically sig-
nificant with initial analysis were then characterized through 
multivariate analysis with logistic regression. Retrospectively 
and prospectively collected specimens were pooled and ana-
lyzed together. Sensitivity, specificity, positive predictive rate, 
and negative predictive rate for LAMP were calculated against 
microscopy both before and after discrepant resolution with 
PCR. After being assessed for significance, multivariate logistic 
regression was utilized to calculate odds ratios. Both important 
variables and statistically significant ones were incorporated 
into the analysis. Admission status was excluded because it 
was a dependent variable, which was influenced by the malaria 
test result. Due to the small sample size of malaria-positive 
patients, variables were dichotomized to allow for reliable ana-
lysis. Continent visited was split into Africa and non-Africa, 
and reason for travel was split into those visiting friends and 
relatives (VFR) and non-VFR. The sample size for subanalyses 
was insufficient without this breakdown. As observed in the 
correlation matrix (Supplementary Table 1), there was reason 
to believe that there was a correlation between pretravel advice 
and prophylaxis taken, so only a single variable, “prophylaxis 
taken,” was utilized in the logistic analysis.
RESULTS
In the prospective arm, 350 specimens were collected from 
a total of 298 consecutive patients enrolled (Figure  1). Two 
4 • OFID • Cheaveau et al
specimens were excluded due to having insufficient samples for 
specimen resolution, leaving 348 specimens. Fifty specimens 
were repeats from some of the participants who initially tested 
positive, as it is routine practice to monitor parasitemia during 
treatment. In the retrospective arm, 29 additional frozen spec-
imens were used to supplement the analysis. The prospective 
and retrospective specimens were combined, so there were 377 
specimens in total. Microscopy and LAMP were available on all 
specimens, but RDT testing was only performed on participants 
in the prospective arm if deemed appropriate (n = 307). Frozen 
specimens had prior microscopy data at the time of diagnosis. 
There was an initial “invalid” test rate with LAMP illumigene M 
of 3.18%; however, all of these resolved with a single repeat test.
In the prospective arm, clinical and epidemiological data were 
analyzed based on the participant’s final malaria result after dis-
crepant resolution. Twenty-five participants out of 298 tested pos-
itive for malaria after discrepant resolution. Twenty-two out of the 
25 participants who tested positive were positive by microscopy; 
the remaining 3 were confirmed by PCR. The median parasitemia 
(interquartile range) was 0.2 (1.275). The mean age in the cohort 
was 32.5 (95% confidence interval [CI], 29.9–35.0) years, and 
50.7% of participants were male (Table 2). Fever was by far the 
most common symptom (265/298; 88.9%), followed by headache 
(124/298; 41.6%), cough (102/298; 34.3%), night sweats (96/298; 
32.2%), and myalgia (92/298; 30.9%). Myalgia was statistically 
more common in the malaria-positive group (16/25; 64.0%) com-
pared with the malaria-negative group (76/273; 27.8%; P < .001) 
(Figure  2). Cough was statistically less common in the malar-
ia-positive group (4/25; 16.0%) compared with the malaria-neg-
ative group (98/273; 35.9%; P =  .047). Malaria-positive patients 
were more likely to be admitted than those who tested negative 
(P < .001). For every year increase in age, the odds of testing pos-
itive for malaria decreased by 6% (odds ratio [OR], 0.94), which 
was statistically significant (95% CI, 0.91–0.98). The odds of 
2 specimens excluded
due to not meeting
inclusion criteria
298 patients enrolled
June 2017 and Jan
2018
348 prospective
specimens
377 specimens
377 specimens
LAMP vs microscopy
12 LAMP invalid
results repeated
79 LAMP pos/
microscopy pos
7 LAMP pos/
microscopy neg
1 LAMP neg/
microscopy pos
290 LAMP neg/
microscopy neg
307 specimens
RDT vs microscopy
29 retrospective
specimens
5 P. vivax
specimens (Canada)
5 P. ovale
specimens (Canada)
13 P. malariae
specimens (Brazil)
6 P. knowlesi
specimens (UK)
12 RDT pos/
microscopy pos
14 RDT pos/
microscopy neg
3 RDT neg/
microscopy pos
278 RDT neg/
microscopy neg
Figure 1. Flow chart of study design and initial results of malaria testing by each method. Abbreviations: LAMP, loop-mediated isothermal amplification; RDT, rapid diag-
nostic test.
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testing positive for males was slightly lower than females (OR, 
0.60; 95% CI, 0.18–1.98), but this was not statistically significant. 
Participants traveling to Africa were significantly more likely to 
test positive for malaria (OR, 18.90; 95% CI, 4.81–74.48) com-
pared with those visiting another location. There was no differ-
ence in the odds for those visiting friends and relatives compared 
with those traveling for other reasons (OR, 0.88; 95% CI, 0.27–
2.89). Antimalarial prophylaxis was protective, with the odds ratio 
for those taking it being 0.17 (95% CI, 0.02–1.48), but this was 
not statistically significant. Evidence of effect measure modifica-
tion (EMM) was looked for between those taking prophylaxis and 
also visiting Africa, but none was observed. In addition, EMM was 
assessed for those taking prophylaxis and also in the VFR group, 
but the sample size was insufficient to perform the analysis.
Age
Male
Malaria prophylaxis taken
Visiting friends and relatives
Traveled to Africa
Myalgia
Cough
Favors malaria negative
0.01 1 100
Favors malaria positive
Figure 2. Odds ratio (OR) and 95% confidence interval (CI) for clinical and epi-
demiological characteristics among study participants for malaria-positive versus 
malaria-negative patients. ORs and 95% CIs enumerated on the x-axis were calcu-
lated using multivariate logistic regression.
Table 2. Comparison of Clinical and Epidemiological Characteristics of Study Participants According to their Malaria Test Outcome (n = 298)
Total Malaria Positive Malaria Negative P  Valuea
No. of patients 298 25 273
Age, mean (95% CI), y 32.5 (29.9–35.0) 25.2 (18.3–32.1) 33.1 (30.5–35.8) .089b
Male, No. (%) 151 (50.7) 13 (52.0) 138 (50.5) .890e
Parasitemia, median (IQR) 0.2 (1.275)
Pretravel advice (n = 208),c No. (%) 69 (33.2) 2 (11.8) 67 (35.1) .061f
Malaria prophylaxis taken (n = 234),c No. (%) 40 (17.1) 2 (9.1) 38 (17.9) .385f
Reason for travel,d No. (%)
Business 15 (5.0) 1 (4.0) 14 (5.1) 1.000f
Not recorded 26 (8.7) 2 (8.0) 24 (8.8) 1.000f
Visiting friends/relatives 129 (43.3) 10 (40.0) 119 (43.6) .692e
Volunteer 1 (0.3) 1 (4.0) 0 .085f
New immigrant 32 (10.7) 6 (24.0) 26 (9.5) .038f
Tourism 89 (29.9) 4 (16.0) 85 (31.1) .111f
Visitor to Canada 6 (2.0) 1 (4.0) 5 (1.8) .414f
Continent visited (n = 287),c No. (%)
Non-Africa 186 (64.8) 4 (16.0) 182 (69.5)
Africa 101 (35.2) 21 (84.0) 80 (30.5) <.001f
Symptoms,d No. (%)
Fever 265 (88.9) 23 (92.0) 242 (88.7) .704f
Night sweats 96 (32.2) 8 (32.0) 88 (32.2) .862e
Myalgia 92 (30.9) 16 (64.0) 76 (27.8) <.001e
Headache 124 (41.6) 13 (52.0) 111 (37.2) .361e
Cough 102 (34.3) 4 (16.0) 98 (35.9) .047f
Sore throat 66 (22.1) 2 (8.0) 64 (23.4) .080f
Diarrhea 66 (22.1) 5 (20.0) 61 (22.3) .808f
Other 8 (2.7) 2 (8.0) 6 (2.2) .148f
Pre-employment 4 (1.3) 0 4 (1.5) 1.000f
Not recorded 12 (4.0) 0 12 (4.4) .608f
New immigrant screen 4 (1.3) 0 4 (1.5) 1.000f
Admitted (n = 295),c No. (%) 47 (15.9) 12 (50.0) 35 (12.9) <.001e
Abbreviations: CI, confidence interval; IQR, interquartile range.
aP value compares malaria-positive with malaria-negative group, missing values excluded.
bT test of means.
cNo. is less than the grand total due to missing data; percentages were calculated excluding missing data and statistical tests excluding missing data.
dTotal does not add up to 100 as participants reported more than 1 symptom.
eChi-square test.
fFisher exact test.
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Data were analyzed both including and excluding retrospec-
tive specimens. For the prospective arm, when repeat testing on 
the same participant was included, 57 specimens tested positive 
by LAMP, whereas 51 tested positive by microscopy (Table 3). 
For microscopy-positive specimens, 38 tested positive for P. fal-
ciparum, 7 for P. vivax, 6 for P. ovale, and none for P. malariae or 
P. knowlesi; the remainder tested negative. Due to repeat testing 
of malaria-positive patients, a test positivity rate of 14.7% was 
obtained in this study. Surveillance data in Calgary from 2013–
2018 and excluding repeat testing within 2 months of an index 
revealed a test positivity rate of 4.4% (unpublished data) used to 
calculate the PPV and NPV. In the prospective arm, LAMP had 
a sensitivity of 98.1% (95% CI, 90.0%–100%) and a specificity 
of 97.6% (95% CI, 95.2%–99.1%) vs microscopy before discrep-
ant resolution for all samples. Based on a prevalence of 4.4%, 
the positive predictive value (PPV) was 65.3%, and the negative 
predictive value (NPV) was 99.9%. Seven specimens were nega-
tive with microscopy but tested positive with LAMP. One spec-
imen was positive with microscopy but negative with LAMP. 
All specimens, both discordant and concordant, were tested 
by RT-PCR for confirmation. Discrepant resolution confirmed 
that the 7 false-positive specimens by LAMP tested positive 
by RT-PCR (Table 4). One false-negative specimen by LAMP 
tested negative by RT-PCR. After discrepant resolution, LAMP 
had a sensitivity of 100% (95% CI, 93.9%–100%) and a specific-
ity of 100% (95% CI, 98.7%–100%) vs microscopy. The PPV and 
NPV were both 100%. For 1 negative specimen by LAMP and 
RT-PCR, only P. ovale gametocytes were found.
When including retrospective specimens, an additional 5 
P. vivax, 5 P. ovale, 13 P. malariae, and 6 P. knowlesi specimens 
were included, so that in total by microscopy there were 38 
P. falciparum specimens, 12 P. vivax, 11 P. ovale, 13 P. malariae, 
and 6 P. knowlesi specimens, with the remainder being negative 
(Table 5). With retrospective specimens included, LAMP had 
a sensitivity of 98.8% (95% CI, 93.2%–100%) and a specificity 
of 97.6% (95% CI, 95.2%–99.1%) vs microscopy. After dis-
crepant resolution, LAMP had a sensitivity of 100% (95% CI, 
95.8%–100%) and a specificity of 100% (95% CI, 98.7%–100%). 
There were no additional discrepancies following inclusion of 
retrospective specimens.
The performance of RDT compared with microscopy was 
evaluated (n  =  307) (Supplementary Table  2). After discrep-
ant resolution using RT-PCR, the sensitivity was 83.3% (95% 
CI, 58.6%–96.4%) and specificity was 96.2% (95% CI, 93.2%–
98.1%). These results correlated with a PPV of 50.2% and an 
NPV of 99.2%. The species-specific performance of LAMP after 
discrepant resolution is shown in Supplementary Table 3.
DISCUSSION
The commonest reason for travel was recent immigrants trave-
ling to visit friends and relatives abroad. These individuals have 
been found in other studies to stay in endemic areas for longer, 
are more likely to stay in local houses, so they are more exposed 
to mosquitos, and are less likely to seek pretravel advice and 
antimalarial prophylaxis [34]. The patient cohort here rep-
resents a typical population presenting with the symptoms of 
malaria. As a result, this study is generalizable to urban centers 
with a large immigrant population across North America and 
Europe. Although numerous studies have examined the role of 
LAMP for the diagnosis of malaria in both the nonendemic and 
endemic settings, this is the first evaluation of LAMP in a “real-
time” prospective trial in returning travelers to North America. 
A  recent meta-analysis found that LAMP appears to have 
excellent sensitivity against PCR [35]. Due to its limit of detec-
tion, LAMP is thought to be particularly useful in diagnosing 
patients with a low parasitemia below the LOD of microscopy 
[26]. It has several advantages over other molecular tests: simple 
to use, no major capital equipment needs, and limited training 
needed [16, 20, 36]. Laboratory technologists were trained in 
illumigene M, and they were able to perform it without diffi-
culty in under an hour once they received the specimen.
Currently, the CDC recommendation for malaria testing is to 
release an RDT result as a preliminary result and then repeat 
thick and thin films every 6 to 8 hours on average 3 times to 
Table 3. Performance of illumigene M Assay vs Microscopy on Returning Travelers in the Prospective Arm Before and After Discrepant Resolution by 
RT-PCR (n = 348)
Before Discrepant 
Resolution
Microscopy
After Discrepant 
Resolution
PCR
Positive Negative Total Positive Negative Total
LAMP Positive 50 7 57 LAMP Positive 57 0 57
Negative 1 290 291 Negative 0 291 291
Total 51 297 348 Total 57 291 348
Percentage 95% CI, % Percentage 95% CI, %
Sensitivity 98.1 90.0–100 Sensitivity 100 93.7–100
Specificity 97.6 95.2–99.1 Specificity 100 98.7–100
Positive predictive valuea 65.3 Positive predictive valuea 100
Negative predictive valuea 99.9 Negative predictive valuea 100
Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction; RT-PCR, real-time polymerase chain reaction.
aBased on a prevalence of 4.4%.
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ensure that no parasites are present [9]. This is accompanied by 
a significant labor cost in both the laboratory and in repeated 
emergency room use. A  previous study from our group pro-
posed a new testing algorithm for malaria with LAMP as the 
firstline diagnostic test [15]. In the nonendemic setting, the 
proportion of malaria tests that are positive is relatively small. 
Repeated testing of patients without malaria based on exist-
ing algorithms results in additional costs to the laboratory and 
hospital. We estimated from this study that a single LAMP test 
with a high NPV would lead to a laboratory cost savings of up to 
USD$13 per malaria test in a nonendemic setting. Further sav-
ings for the hospital may be possible resulting from the earlier 
discharge of the patient from the emergency room or doctor's 
office. Multiple studies have found that LAMP had an excellent 
NPV compared with PCR. However, they are often retrospec-
tive, do not run continuously, and/or commonly have a small 
number of non–P. falciparum species included.
A strength of the study is that all species of malaria were tested 
and correctly identified, which is essential if this test is to be used 
routinely. The study was prospective in nature and ran continu-
ously in real time for 8 months to reflect current practice, albeit 
supplemented with retrospective specimens. Technologists were 
easily trained and were able to complete testing with illumigene 
M without supervision. This has potential advantages after-
hours as technologists may not be experienced with reading 
the thick films required to ultimately rule out infection. Based 
on the LAMP sensitivity and NPV (100%) found in this study, 
patients presenting after-hours who test negative can safely be 
discharged home within 1 hour of specimen receipt at the lab-
oratory (Figure 3). The lower sensitivity of RDT (83.3%) in this 
study does not permit this confidence, especially for non–P. fal-
ciparum species, for which it fails more routinely to detect infec-
tion. Previously, the time to final reading of the thick film (where 
sensitivity is achieved) was 9 to 24 hours, depending on special-
ist technologist availability, because of the lack of confidence in 
the RDT result. The ability to discharge patients leads to a cost 
savings for the health facility because patients do not have to 
re-attend for repeat microscopy smears.
A limitation of this study is that the same technologist often 
performed LAMP, microscopy, and RDT testing for each speci-
men. It was not feasible to have multiple technologists available 
who could perform testing, so consequently operators were not 
blinded to other results. This may have introduced some mis-
classification bias. For discordant results, PCR testing occurred 
off-site and operators were blinded, thereby reducing misclas-
sification bias for the most important results. Also, although 
P. knowlesi samples were contrived from a lab strain, LAMP has 
been able to detect patient samples on dried blood spots by our 
group (our unpublished observations) and patient whole-blood 
samples by others (Martin et al., unpublished data, 2018).
A limitation of the illumigene M platform is that it does not 
identify the species of malaria. This is not essential as a rapid 
screening test. Positive LAMP tests can be followed up with 
microscopy to determine species and parasitemia. An “invalid” 
rate of 3.18% was observed. The reasons for this are unclear 
(possibly due to high parasitemia, DNA amplification inhibi-
tor, delay in the extraction process), but this study did have a 
smaller proportion of invalid results compared with other rele-
vant studies [15, 30].
Table 4. Results of Discrepant Resolution by Sample Number (n = 8)
Sample  
Number Microscopy illumigene M
Alternate 
PCR Final
018 Neg Pos Pos True positive – P. falciparum
035 Neg Pos Pos True positive – P. falciparum
068 Neg Pos Pos True positive – P. falciparum
095 Neg Pos Pos True positive – P. vivax
112 Neg Pos Pos True positive – P. falciparum
122 Po gametocytes Neg Neg True negative
253 Neg Pos Pos True positive – P. falciparum
265 Neg Pos Pos True positive – P. falciparum
Abbreviation: PCR, polymerase chain reaction; Po, plasmodium ovale.
Table 5. Performance of illumigene M Assay vs Microscopy on Returning Travelers in the Prospective and Retrospective Arms Combined (n = 377) Before 
and After Discrepant Resolution
Before Discrepant 
Resolution
Microscopy
After Discrepant 
Resolution
PCR
Positive Negative Total Positive Negative Total
LAMP Positive 79 7 86 LAMP Positive 86 0 86
Negative 1 290 291 Negative 0 291 291
Total 80 297 377 Total 86 291 377
Percentage  95% CI, % Percentage 95% CI, %
Sensitivity 98.8 93.2–100 Sensitivity 100 95.8–100
Specificity 97.6 95.2–99.1 Specificity 100 98.7–100
Positive predictive valuea 65.5 Positive predictive valuea 100
Negative predictive valuea 100 Negative predictive valuea 100
Abbreviations: CI, confidence interval; LAMP, loop-mediated isothermal amplification; PCR, polymerase chain reaction.
aBased on a prevalence of 4.4%.
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 In this study, invalid results resolved with single repeated 
testing; however, they caused a delay in diagnosis. Specimens 
that did not resolve with repeated testing would require an 
alternative method to be used.
In a nonendemic setting where the prevalence of malaria in 
returning travelers is relatively low, LAMP is able to rule out 
malaria with a faster turnaround time without the need for 
repeat testing. A  novel, highly sensitive testing algorithm for 
malaria screening with associated cost savings in the nonen-
demic setting is proposed.
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